1 June 2022
EMA/305129/2022
EMEA/H/C/000964

Public statement

Neurobloc (botulinum toxin type B)

Cessation of marketing in the European Union

On 19 April 2021, the European Medicines Agency was notified by the marketing authorisation holder of Neurobloc, Sloan Pharma S.a.r.l, of its decision to stop marketing the product in the EU. This decision was based on commercial reasons.

Neurobloc was granted marketing authorisation in the EU on 22 January 2001 for the treatment of cervical dystonia in adults.

Therapeutic alternatives are available throughout the European Union. Patients taking Neurobloc or participating in a clinical trial are advised to consult their physician.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union